Bone loss after allogeneic haematopoietic stem cell transplantation: a pilot study on the use of zoledronic Acid.

about

Bone loss after allogeneic haematopoietic stem cell transplantation: a pilot study on the use of zoledronic Acid.

Item

http://www.wikidata.org/entity/Q35895664

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Bone loss after allogeneic hae ...... on the use of zoledronic Acid.

@ast

Bone loss after allogeneic hae ...... on the use of zoledronic Acid.

@en

type

Item

label

Bone loss after allogeneic hae ...... on the use of zoledronic Acid.

@ast

Bone loss after allogeneic hae ...... on the use of zoledronic Acid.

@en

prefLabel

Bone loss after allogeneic hae ...... on the use of zoledronic Acid.

@ast

Bone loss after allogeneic hae ...... on the use of zoledronic Acid.

@en

P1476

Bone loss after allogeneic hae ...... on the use of zoledronic Acid.

@en

P2093

Andrea Baur-Melnyk

http://www.w3.org/2001/XMLSchema#string

Andreas Hausmann

http://www.w3.org/2001/XMLSchema#string

Georg Ledderose

http://www.w3.org/2001/XMLSchema#string

Hans Joachim Stemmler

http://www.w3.org/2001/XMLSchema#string

Hans-Jochem Kolb

http://www.w3.org/2001/XMLSchema#string

Johanna Tischer

http://www.w3.org/2001/XMLSchema#string

Johanna Ullmann

http://www.w3.org/2001/XMLSchema#string

Sandra Geiger

http://www.w3.org/2001/XMLSchema#string

Susanne Fritsch

http://www.w3.org/2001/XMLSchema#string

Wolfgang Hill

http://www.w3.org/2001/XMLSchema#string

P2860

Osteoporosis after blood and marrow transplantation: clinical aspects.

The skeletal site-differential changes in bone mineral density following bone marrow transplantation: 3-year prospective study

The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.

Posttransplantation bone disease.

Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients.

Significant and persistent loss of bone mineral density in the femoral neck after haematopoietic stem cell transplantation: long-term follow-up of a prospective study.

Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study.

Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation.

Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis.

Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation.

P304

858590

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2012/858590

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224879750

http://www.w3.org/2001/XMLSchema#string

P698

22550587

http://www.w3.org/2001/XMLSchema#string

P932

3328888

http://www.w3.org/2001/XMLSchema#string